Therapeutic plasma exchange, also called plasmapheresis, filters the liquid part of your blood, removes it, and replaces it with albumin or donor plasma. For a defined set of diseases it is established, sometimes life-saving treatment: thrombotic thrombocytopenic purpura, Guillain-Barre syndrome, myasthenia gravis, and several autoimmune kidney and nerve conditions, where randomized trials support it and professional apheresis guidelines rank it first-line. A separate, newer idea uses the same machine: that removing old plasma, or replacing it with plasma from young donors, might slow aging or treat dementia.
That idea comes from mouse experiments and one mixed Alzheimer trial, and in 2019 the FDA warned against clinics selling young-donor plasma infusions for aging. This page keeps the two apart: where plasma exchange is established treatment, what the aging research actually shows, why the field now leans on diluting old plasma more than on adding young factors, and the risks of the procedure itself, from low calcium to catheter infection. It is education, and it describes no protocol you would run on your own.
Findings & Outcomes
What It Is
Therapeutic plasma exchange separates blood into its cells and its plasma, the straw-colored fluid the cells float in, discards the plasma, and returns the cells with a replacement fluid, usually human albumin and sometimes donor plasma. An apheresis machine does the separation through a large intravenous line or a central catheter, over one to a few hours, and a course is usually several sessions across days or weeks. The aim is to pull out substances that live in the plasma and drive a disease: rogue antibodies, immune complexes, and other large molecules that ordinary drugs clear slowly or not at all.
For a defined list of diseases this is standard care, and for some it is the difference between a fatal illness and a survivable one. The aging use relies on the same machine and almost nothing else.
Anatomy
1Separating the blood
Blood is drawn from a vein or a central catheter into an apheresis machine that spins or filters it, separating the red and white cells from the plasma. The cells go back to the body continuously, and the plasma is removed. A large volume of blood sits outside the body in the tubing during the session, so the line and the machine carry most of the procedural risk.
2Removing the plasma
The removed plasma carries whatever large molecules were dissolved in it, including the autoantibodies and immune complexes that drive certain diseases. This is the therapeutic action for the established uses: one session lowers a circulating antibody within hours, faster than the body clears it and faster than most drugs act, which is why plasma exchange is used when a disease is moving fast.
3Replacing the volume
The plasma taken out has to be replaced, usually with a solution of human albumin, sometimes with donor plasma when clotting factors also need replacing. To keep blood from clotting inside the machine, the circuit runs on citrate, which binds calcium. That keeps the tubing clear and is also the source of the most common side effect, a temporary drop in the calcium available to the body.
How It Works
Plasma exchange works by physically pulling molecules out of the blood, not by adding a drug. In the established disease uses the target is a specific harmful substance floating in the plasma: the autoantibody attacking nerves in Guillain-Barre syndrome or myasthenia gravis, the antibody against a clotting enzyme in thrombotic thrombocytopenic purpura, or the antibody attacking kidney and lung in anti-GBM disease. Lowering that substance fast buys time, and in the fast-moving conditions it changes the outcome. The replacement fluid restores blood volume, and when donor plasma is used it restores clotting proteins the exchange also removed.
The aging idea runs on a less certain logic. Plasma composition changes with age, and animal work suggests that some of what builds up in old plasma holds tissues back. That leaves two possible explanations, and they point to different treatments:
- Add young factors. If young plasma supplies something an old body has lost, the fix is to infuse young plasma.
- Remove old factors. If old plasma carries harmful factors, the fix is to remove or dilute them, which is what a plain plasma exchange with albumin already does.
The animal and human work below has moved weight toward removal, which is why the studied treatment is plasma exchange with albumin and not young-donor plasma. For where this sits among the drivers of aging, see the biology of aging.
What the Evidence Shows
The findings below split into two groups with very different evidence behind them.
The established disease uses are the solid ground. For thrombotic thrombocytopenic purpura, Guillain-Barre syndrome, myasthenia gravis, anti-GBM disease, and several other autoimmune nerve and kidney disorders, plasma exchange is standard care: graded first-line, Category I, by the American Society for Apheresis and backed by randomized trials. These conditions are the reason the procedure and the machines exist. Category I is a verdict about a specific disease, and it says nothing about aging, where the guidelines grade plasma exchange nowhere.
The aging use is the frontier, and its evidence thins as it moves from mice to people. The mouse experiments are striking, but they share far more than plasma between the animals, and no human treatment reproduces a shared circulation. The one substantial human trial in an aging-related disease is AMBAR, in Alzheimer disease, and it needs reading with care on two counts:
- It was funded by Grifols, the plasma-products company that stood to gain, and several of its authors were Grifols employees, so it is not an independent result.
- Its overall effect on the main cognitive scale (ADAS-Cog) was a statistical trend, not a clear result (P=.06). The signal that reached significance sat in the moderate-disease subgroup, and the mild subgroup did not change.
For healthy aging, as distinct from Alzheimer disease, there is no completed trial showing benefit at all.
In 2019 the FDA warned against clinics charging thousands of dollars to infuse young-donor plasma for aging and memory, stating that the infusions have not been shown to help and carry the risks of any plasma transfusion.
The Research & Studies
Everything here is based on the research we have collected and checked, sorted into groups and ordered with the strongest evidence first. Click any claim to open the studies behind it.
How it works
Plasma exchange removes circulating antibodies faster than the body or drugs can clear them
A machine takes the liquid part of your blood out, throws it away with whatever harmful large molecules were floating in it, and gives the cells back with a replacement fluid. It lowers a circulating substance faster than the body or most drugs can.
In therapeutic plasma exchange, blood is drawn into an apheresis device that separates plasma from cellular elements by centrifugation or membrane filtration. The removed plasma carries immunoglobulins, immune complexes, paraproteins and protein-bound substances. Replacement is typically 5% human albumin, with fresh frozen plasma used when coagulation factors must also be replaced. Citrate is infused into the circuit to chelate calcium and prevent clotting. One to 1.5 plasma volumes are exchanged per session, and a treatment course is usually several sessions. The therapeutic rationale for the established indications is rapid reduction of a pathogenic plasma constituent.
The study · 1
Padmanabhan et al., Guidelines on the Use of Therapeutic Apheresis in Clinical Practice, ASFA Eighth Special Issue · J Clin Apher 2019;34(3):171-354
Counts once: this finding and 1 other here come from the same source, so they are one body of evidence, not separate confirmations.
Sharing a young mouse's blood restored aged muscle and liver stem cells (mice)
When an old mouse is surgically connected to a young mouse so they share blood, the old mouse's stem cells start behaving younger. It shows that something carried in the blood can shift aging, at least in mice.
Conboy and colleagues (2005) joined the circulations of young and old mice (heterochronic parabiosis) and found that exposure to a young systemic environment restored the regenerative capacity of aged muscle satellite cells and liver progenitor cells, reactivating molecular signaling that had declined with age. This established that circulating factors, not only intrinsic cell aging, govern aspects of tissue aging. It is the foundational experiment behind the young-blood field.
The study · 1
Conboy et al., Rejuvenation of aged progenitor cells by exposure to a young systemic environment · Nature 2005;433(7027):760-764
Replacing about half of old mice's plasma with saline-albumin rejuvenated tissue, no young blood added
When researchers diluted old mouse blood with a simple saline-and-albumin mix and added no young blood at all, the old tissues still improved. That points to removing bad factors, not adding young ones, as a big part of what is going on.
Mehdipour and colleagues (2020) performed a neutral blood exchange in old mice, replacing roughly 50% of plasma with saline containing 5% albumin. This procedure, which adds no young plasma, improved regeneration and reduced markers of aging in muscle, liver and brain, comparable in several respects to heterochronic effects. The authors argued that dilution of pro-aging or inhibitory factors in old plasma, and possibly the replacement of albumin itself, drives the benefit. This reframes the mechanism away from young-factor transfer toward removal, and is the rationale for testing plain plasma exchange with albumin rather than young-donor plasma.
The study · 1
Mehdipour et al., Rejuvenation of three germ layers tissues by exchanging old blood plasma with saline-albumin · Aging (Albany NY) 2020;12(10):8790-8819
Autoimmune Neuro
About 78% survive TTP with plasma exchange, versus 63% with plasma infusion
Thrombotic thrombocytopenic purpura used to kill most people who got it. Plasma exchange changed that: in the trial that set the standard, more patients survived and recovered with plasma exchange than with plasma infusion.
Rock and colleagues (1991) randomized 102 patients with thrombotic thrombocytopenic purpura, 51 to plasma exchange and 51 to plasma infusion. Plasma exchange produced more responses at the early time points and better survival, with roughly 78% of the exchange group versus 63% of the infusion group alive at six months. TTP is caused by autoantibodies against the ADAMTS13 enzyme; plasma exchange both removes the antibody and replaces the deficient enzyme, which is why exchange outperforms infusion alone. This trial established plasma exchange as first-line therapy for TTP.
The study · 1
Rock et al., Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura (Canadian Apheresis Study Group) · N Engl J Med 1991;325(6):393-397
Plasma exchange speeds Guillain-Barre recovery, with fewer left severely weak at one year
In Guillain-Barre syndrome, where the immune system attacks the nerves and causes rising paralysis, plasma exchange helps people recover faster and leaves fewer with lasting severe weakness.
Raphael and colleagues (2012 Cochrane review) pooled six randomized trials of plasma exchange in Guillain-Barre syndrome. Compared with supportive care, plasma exchange shortened time on a ventilator and time to recover walking, increased the proportion recovering full strength at one year, and reduced severe residual weakness, with the largest benefit when started within the first two weeks of symptoms. The mechanism is removal of the circulating autoantibodies and complement factors driving the acute demyelinating attack. Plasma exchange and intravenous immunoglobulin are considered equivalent first-line options.
The study · 1
Raphael et al., Plasma exchange for Guillain-Barre syndrome · Cochrane Database Syst Rev 2012;(7):CD001798
Apheresis guidelines rank plasma exchange first-line (Category I) for TTP, Guillain-Barre and myasthenia crisis
Plasma exchange is a recognized standard treatment for a specific list of diseases, not a general therapy. Kidney and nerve conditions driven by rogue antibodies are where it belongs, graded by the professional apheresis society.
The ASFA Eighth Special Issue (Padmanabhan et al., 2019) grades apheresis indications by evidence quality and assigns a category from I (accepted first-line) to IV (evidence suggests harm or ineffectiveness). Plasma exchange holds Category I status for thrombotic thrombocytopenic purpura, Guillain-Barre syndrome, chronic inflammatory demyelinating polyneuropathy, myasthenia gravis (moderate-severe or crisis), anti-GBM disease (Goodpasture), and others. The guidelines are periodically updated as trial evidence accumulates. This grading is the reference standard clinicians use to decide when plasma exchange is indicated.
The study · 1
Padmanabhan et al., Guidelines on the Use of Therapeutic Apheresis in Clinical Practice, ASFA Eighth Special Issue · J Clin Apher 2019;34(3):171-354
Counts once: this finding and 1 other here come from the same source, so they are one body of evidence, not separate confirmations.
Cognition
Young blood improved memory and synaptic plasticity in aged mice
Old mice given young blood, or plain young plasma, did better on memory tests and showed signs of renewed connections between brain cells. This is the animal result the young-plasma idea is built on.
Villeda and colleagues (2014) showed that young blood, delivered by heterochronic parabiosis or by repeated intravenous injection of young mouse plasma, reversed several age-related impairments in the aged mouse hippocampus, improving contextual fear conditioning and spatial learning and increasing dendritic spine density and long-term potentiation. The work implicated specific plasma factors in the effect. It is a strong animal signal that plasma constituents can influence brain aging.
The study · 1
Villeda et al., Young blood reverses age-related impairments in cognitive function and synaptic plasticity in mice · Nat Med 2014;20(6):659-663
Plasma exchange with albumin slowed Alzheimer decline about 61% in the moderate subgroup (AMBAR)
In the one large human trial, plasma exchange with albumin slowed the loss of thinking and everyday function in Alzheimer disease, most clearly in people who were already at a moderate stage. It is one encouraging but mixed result, not a settled treatment.
Boada and colleagues (2020) reported the AMBAR (Alzheimer Management By Albumin Replacement) trial: 347 patients with mild-to-moderate Alzheimer disease randomized to sham or to plasma exchange with albumin, with or without intravenous immunoglobulin, over 14 months. Treated patients showed less decline on the co-primary endpoints ADAS-Cog (cognition) and ADCS-ADL (daily function); the moderate-disease subgroup showed roughly 61% less functional and cognitive decline versus placebo, while the mild subgroup showed no significant change. The proposed mechanism is removal of albumin-bound amyloid-beta and other plasma factors. Limitations include a single trial, subgroup-dependent effects, and the difficulty of fully blinding an invasive sham procedure.
The study · 1
Boada et al., A randomized, controlled clinical trial of plasma exchange with albumin replacement for Alzheimer's disease (AMBAR) · Alzheimers Dement 2020;16(10):1412-1425
Longevity And Mortality
No completed human trial shows young-donor plasma slows aging
In people, there is no finished controlled trial showing that young-donor plasma slows aging or sharpens memory in a healthy person. Scientists are still debating whether the effect, if any, comes from young factors added or old factors removed.
A review by Kang and colleagues (2020) surveys the circulating factors implicated in rejuvenation and describes the two competing frameworks, young beneficial factors versus removal or dilution of pro-aging factors, as active hypotheses supported chiefly by rodent work. In humans, the direct evidence for young-donor plasma slowing aging is absent; the only sizable controlled human data on plasma exchange in an aging-related condition is the AMBAR Alzheimer trial, which used albumin replacement rather than young plasma. Commercial young-plasma infusion for aging preceded any supporting human trial.
The study · 1
Kang & Yang, Circulating plasma factors involved in rejuvenation · Aging (Albany NY) 2020;12(22):23394-23408
Go Deeper
- The biology of aging: where blood-borne factors and plasma exchange sit among the hallmarks of aging, and how to read a mouse rejuvenation result against the human evidence.
- Rapamycin: another longevity frontier where a strong animal record and an approved medical use sit beside a large off-label experiment.
- IV therapy and NAD: a neighboring anti-aging pitch delivered by vein, and the same gap between moving a marker and changing an outcome.
- Peptides: a category where a few approved treatments sit alongside a large unregulated market, and how to keep the two apart.
The Chinese Medicine View
Therapeutic plasma exchange is a product of modern transfusion medicine and engineering, with no entry in the classical Chinese pharmacopoeia. No historical text assigns a channel, a temperature, or a flavor to an apheresis procedure, and no traditional practice resembles removing and replacing the fluid of the blood. Here the tradition is a lens for thinking about the procedure, not evidence for it, and this section borrows no classical claim, because none exists. Nothing here suggests that any herb or formula reproduces what plasma exchange does.
The tradition does reason carefully about the territory the procedure touches, which is Blood. In Chinese medicine, Blood is a precious substance that nourishes the whole body and houses the Shen, the mind and spirit, and the tradition treats it as something to conserve and build, not to spend freely.
That framing lands differently on the two uses:
- When a pathogenic factor drives a disease, removing it has a clear parallel in the long tradition of clearing what is harmful so the body can right itself. The caution the tradition would add is that removal also depletes, so it belongs where the need is clear and the person can bear it.
- When the aim is to slow aging in a well person, the tradition would be more reserved. Draining and replacing Blood in someone who is not deficient does not fit the logic of tonification, which builds a deficiency only where one exists and warns that forcing a healthy system adds no vitality.
This is a way of connecting a modern procedure to a framework the tradition has long reasoned about, not a claim that Chinese medicine endorses or explains plasma exchange. The classical concepts belong to the tradition as it uses them, and the evidence for the procedure rests on its own trials, which are strong for specific diseases and early for aging.
Cautions For This Practice
Everything to be aware of is here, in one place. This practice suits most healthy people; a few situations call for real care.
Serious apheresis reactions are uncommon; low-calcium tingling, low blood pressure and faintness are the usual ones
Mortzell Henriksson and colleagues (2016) reported updated World Apheresis Association registry data across many thousands of procedures. Adverse events were recorded in a modest percentage of procedures, dominated by citrate-related paresthesia and tetany, hypotension, vasovagal reactions, and urticarial reactions to replacement fluid; the rate and severity depended on the replacement fluid (donor plasma carrying more allergic risk than albumin) and on patient condition. Severe events were rare. Vascular access, particularly central venous catheters, contributes additional infection, bleeding and mechanical risks not captured as procedural reactions.Mortzell Henriksson et al., Adverse events in apheresis: An update of the WAA registry data
Citrate in the circuit lowers calcium, causing tingling and cramps unless calcium is given
Zhao and colleagues (2018) compared two methods of prophylactic calcium gluconate infusion during therapeutic plasma exchange and documented the expected fall in plasma ionized calcium driven by citrate chelation, along with the symptomatic hypocalcemia it causes when uncorrected and its prevention with calcium supplementation. Citrate toxicity is the most common metabolic complication of apheresis; it is generally mild and self-limited but can progress to tetany or arrhythmia at higher citrate loads, which is why ionized calcium is monitored during exchange.Zhao & Linden, Prophylactic infusion of calcium gluconate to prevent a symptomatic fall in plasma ionized calcium during therapeutic plasma exchange
A clinical procedure, not a home practice
Plasma exchange requires an apheresis machine, trained staff, large intravenous access, and monitoring. It is done in hospitals and specialist units, and it belongs there. There is no at-home version, and nothing on this page is a protocol to arrange on your own. For the established disease uses it is a decision made with the treating team; for aging it is experimental.
The intravenous line and catheter
The procedure needs a large-bore line or a central catheter, and that access carries the clearest risks: local and bloodstream infection, bleeding, vein injury, and, with central lines, uncommon but serious events such as a punctured lung or a clot. A large volume of blood is outside the body in the circuit at once, so the setting and the staff matter as much as the fluid.
Citrate and low calcium
The circuit uses citrate to stop blood clotting in the machine, and citrate binds calcium, so a temporary fall in available calcium is the most common side effect. It shows up as tingling around the mouth and fingers and, if it goes further, muscle cramps or heart-rhythm effects, which is why units monitor calcium and often give it during the session. It is manageable, and units expect it.
Blood pressure, fluid shifts, and reactions
Moving a large volume of blood through a machine can drop blood pressure and cause lightheadedness or fainting, and replacement fluids can trigger allergic reactions, more so with donor plasma than with albumin. Removing plasma also removes clotting factors and antibodies the body needs, so repeated sessions can raise bleeding and infection risk until those recover.
Young-donor plasma for aging: cost and a benefit not shown
Clinics have charged thousands of dollars per infusion of young-donor plasma marketed for aging and memory. The FDA warned in 2019 that these infusions have not been shown to benefit aging or dementia, and they carry the standard risks of any plasma transfusion, including allergic reactions, infection transmission, and volume overload. Paying out of pocket for a benefit that human trials have not shown is the specific caution here.
A conversation for a clinician
For the diseases where plasma exchange is standard care, the decision sits with the specialist team treating you. For aging or general wellness, no trial supports the risk and cost, and the appropriate step is a conversation with a knowledgeable clinician, not a clinic booking. This page describes the landscape and gives no protocol.
Start slow, be smart, read the research, and consult a professional if you have any concerns. This is here to inform your choice, not make it for you.
Common Questions
Is plasma exchange a proven treatment?
Yes, for a specific set of conditions. The American Society for Apheresis grades plasma exchange as a first-line (Category I) treatment for diseases including thrombotic thrombocytopenic purpura, Guillain-Barre syndrome, myasthenia gravis, and certain autoimmune kidney and nerve disorders, based on randomized trials. In thrombotic thrombocytopenic purpura it turned a usually fatal disease into a usually survivable one. The separate, newer use of plasma exchange or young-donor plasma to slow aging in a healthy person is not established.
Does young blood or plasma slow aging in people?
It has not been shown to. The idea comes from mouse experiments in which a young and an old animal shared a circulation and the older one improved, and from one Alzheimer trial, AMBAR, that found a modest, mixed slowing of decline using plasma exchange with albumin, not young-donor plasma. For healthy aging there is no completed trial showing benefit, and the FDA warned in 2019 against clinics selling young-plasma infusions for aging, stating that the infusions have not been shown to help and carry known risks.
What is the difference between removing old plasma and adding young plasma?
They are two explanations for the same animal results, and they point to different treatments. One holds that young plasma adds beneficial factors; the other holds that old plasma contains harmful factors that removal or dilution takes away. A mouse experiment that replaced half the old plasma with plain saline and albumin, adding no young blood, still produced rejuvenation, which favors removal as at least part of the mechanism. That is why the Alzheimer research has tested plain plasma exchange with albumin and not young-donor plasma.
What are the risks of plasma exchange?
The main ones come from the line and the machine, not from any drug. The large intravenous access can cause infection, bleeding, or vein injury, and central lines carry uncommon but serious risks. The citrate used to keep blood from clotting binds calcium, so a temporary drop in calcium, felt as tingling and cramps, is the most common side effect. Blood pressure can fall, replacement fluids can cause allergic reactions, and repeated sessions remove clotting factors and antibodies until the body replaces them.
Can a Chinese herb or formula do what plasma exchange does?
No, and this page makes no such claim. Plasma exchange is a mechanical procedure that removes molecules from the blood, and no herb or formula reproduces that action. What the Chinese medicine tradition offers here is a lens: it treats Blood as precious, something to conserve and build, not to spend, and it would reserve a powerful, depleting intervention for a clear need, not reach for it in a well person. That is a way of thinking about the procedure, not an equivalent treatment.
Explore Related
Other pages this one connects to, by the evidence they share, the outcomes they touch, and the ground they cover.
All 11 sources on this page independently checked and cross-referenced.
Thomas Dehli, Founder & Editor, Sacred Lotus
Sacred Lotus has published Chinese medicine reference material since 2001. Integrative pages are held to the same standard as the herb and formula library: cite the source, grade the claim at its real strength, and say where the research has not looked. This page is educational and it is not medical advice. Last reviewed and updated August 9, 2026.
Evidence strength
How confidently the research supports a claim. Strength describes the evidence, not our endorsement.